Article
RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies
6 May 2017
Abstract excerpt
Targeting deficient mechanisms of cellular DNA repair still represents the basis for the treatment of the majority of solid tumors, and increased DNA repair capacity is a hallmark mechanism of resistance not only to DNA-damaging treatments such as cytotoxic drugs and radiotherapy, but also to small molecule targeted drugs such as inhibitors of poly-ADP ribose polymerase (PARP). Hence, there is substantial medical...
Topics
Join the communities discussing this publication.